466 related articles for article (PubMed ID: 7630640)
1. Determination of sequences responsible for the differential regulation of Myc function by delta Max and Max.
Västrik I; Mäkelä TP; Koskinen PJ; Alitalo K
Oncogene; 1995 Aug; 11(3):553-60. PubMed ID: 7630640
[TBL] [Abstract][Full Text] [Related]
2. Mmip1: a novel leucine zipper protein that reverses the suppressive effects of Mad family members on c-myc.
Gupta K; Anand G; Yin X; Grove L; Prochownik EV
Oncogene; 1998 Mar; 16(9):1149-59. PubMed ID: 9528857
[TBL] [Abstract][Full Text] [Related]
3. Both the helix-loop-helix and the leucine zipper motifs of c-Myc contribute to its dimerization specificity with Max.
Davis LJ; Halazonetis TD
Oncogene; 1993 Jan; 8(1):125-32. PubMed ID: 8423990
[TBL] [Abstract][Full Text] [Related]
4. Differential effects by Mad and Max on transformation by cellular and viral oncoproteins.
Cerni C; Bousset K; Seelos C; Burkhardt H; Henriksson M; Lüscher B
Oncogene; 1995 Aug; 11(3):587-96. PubMed ID: 7630643
[TBL] [Abstract][Full Text] [Related]
5. Mutational analysis of Max: role of basic, helix-loop-helix/leucine zipper domains in DNA binding, dimerization and regulation of Myc-mediated transcriptional activation.
Reddy CD; Dasgupta P; Saikumar P; Dudek H; Rauscher FJ; Reddy EP
Oncogene; 1992 Oct; 7(10):2085-92. PubMed ID: 1408152
[TBL] [Abstract][Full Text] [Related]
6. Gene-regulatory properties of Myc helix-loop-helix/leucine zipper mutants: Max-dependent DNA binding and transcriptional activation in yeast correlates with transforming capacity.
Crouch DH; Fisher F; Clark W; Jayaraman PS; Goding CR; Gillespie DA
Oncogene; 1993 Jul; 8(7):1849-55. PubMed ID: 8510929
[TBL] [Abstract][Full Text] [Related]
7. Analysis of the Myc and Max interaction specificity with lambda repressor-HLH domain fusions.
Marchetti A; Abril-Marti M; Illi B; Cesareni G; Nasi S
J Mol Biol; 1995 May; 248(3):541-50. PubMed ID: 7752223
[TBL] [Abstract][Full Text] [Related]
8. Transcriptional activation by the human c-Myc oncoprotein in yeast requires interaction with Max.
Amati B; Dalton S; Brooks MW; Littlewood TD; Evan GI; Land H
Nature; 1992 Oct; 359(6394):423-6. PubMed ID: 1406955
[TBL] [Abstract][Full Text] [Related]
9. c-Myc does not require max for transcriptional activity in PC-12 cells.
Ribon V; Leff T; Saltiel AR
Mol Cell Neurosci; 1994 Jun; 5(3):277-82. PubMed ID: 8087425
[TBL] [Abstract][Full Text] [Related]
10. The NMR solution structure of a mutant of the Max b/HLH/LZ free of DNA: insights into the specific and reversible DNA binding mechanism of dimeric transcription factors.
Sauvé S; Tremblay L; Lavigne P
J Mol Biol; 2004 Sep; 342(3):813-32. PubMed ID: 15342239
[TBL] [Abstract][Full Text] [Related]
11. Insights into the mechanism of heterodimerization from the 1H-NMR solution structure of the c-Myc-Max heterodimeric leucine zipper.
Lavigne P; Crump MP; Gagné SM; Hodges RS; Kay CM; Sykes BD
J Mol Biol; 1998 Aug; 281(1):165-81. PubMed ID: 9680483
[TBL] [Abstract][Full Text] [Related]
12. Functional analysis of the carboxy-terminal transforming region of v-Myc: binding to Max is necessary, but not sufficient, for cellular transformation.
Min S; Mascarenhas NT; Taparowsky EJ
Oncogene; 1993 Oct; 8(10):2691-701. PubMed ID: 8378081
[TBL] [Abstract][Full Text] [Related]
13. DNA binding by N- and L-Myc proteins.
Ma A; Moroy T; Collum R; Weintraub H; Alt FW; Blackwell TK
Oncogene; 1993 Apr; 8(4):1093-8. PubMed ID: 8455937
[TBL] [Abstract][Full Text] [Related]
14. myc, max, and a novel rlf-L-myc fusion protein in small-cell lung cancer.
Västrik I; Mäkelä TP; Koskinen PJ; Saksela K; Alitalo K
Princess Takamatsu Symp; 1991; 22():307-18. PubMed ID: 1668890
[TBL] [Abstract][Full Text] [Related]
15. The basic region/helix-loop-helix/leucine zipper domain of Myc proto-oncoproteins: function and regulation.
Lüscher B; Larsson LG
Oncogene; 1999 May; 18(19):2955-66. PubMed ID: 10378692
[TBL] [Abstract][Full Text] [Related]
16. Structure, function, and dynamics of the dimerization and DNA-binding domain of oncogenic transcription factor v-Myc.
Fieber W; Schneider ML; Matt T; Kräutler B; Konrat R; Bister K
J Mol Biol; 2001 Apr; 307(5):1395-410. PubMed ID: 11292350
[TBL] [Abstract][Full Text] [Related]
17. Design and properties of a Myc derivative that efficiently homodimerizes.
Soucek L; Helmer-Citterich M; Sacco A; Jucker R; Cesareni G; Nasi S
Oncogene; 1998 Nov; 17(19):2463-72. PubMed ID: 9824157
[TBL] [Abstract][Full Text] [Related]
18. Viral mutations enhance the Max binding properties of the vMyc b-HLH-LZ domain.
Crouch DH; Fisher F; La Rocca SA; Goding CR; Gillespie DA
Nucleic Acids Res; 2005; 33(16):5235-42. PubMed ID: 16166655
[TBL] [Abstract][Full Text] [Related]
19. Evolutionary relationships and functional conservation among vertebrate Max-associated proteins: the zebra fish homolog of Mxi1.
Schreiber-Agus N; Chin L; Chen K; Torres R; Thomson CT; Sacchettini JC; DePinho RA
Oncogene; 1994 Nov; 9(11):3167-77. PubMed ID: 7936639
[TBL] [Abstract][Full Text] [Related]
20. Low molecular weight inhibitors of Myc-Max interaction and function.
Yin X; Giap C; Lazo JS; Prochownik EV
Oncogene; 2003 Sep; 22(40):6151-9. PubMed ID: 13679853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
